Market Research Logo

Europe Hyperphosphatemia Drug Market Forecast 2019-2027

Europe Hyperphosphatemia Drug Market Forecast 2019-2027

KEY FINDINGS

The Europe hyperphosphatemia drug market is expected to grow at a CAGR of 15.63% during the forecast period of 2019-2027. The market revenue is estimated to increase from $xx million in 2018 to $xx million by the end of 2027. Rising elderly citizenry, altering dietary habits and surging cases of osteoporosis are responsible for the expansion of the hyperphosphatemia drug market.

MARKET INSIGHTS

The Calcium-based phosphate binder’s formulation containing substituted aluminium-based phosphorus binders that act like calcium supplements are expected to dominate the hyperphosphatemia drugs market during the forecast period; with a market share of xx%, as observed in 2018. The other phosphate binders include aluminium-based phosphate binders and magnesium-based phosphate binders that are increasingly being used for treating the hyperphosphatemia conditions in dialysis patients. In spite of such formidable demand of the drug for kidney-related ailments, the market is facing certain constraints because of some limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the available hyperphosphatemia drugs such as lanthanum, sevelamer, and others.

COMPETITIVE INSIGHTS

A majority of companies are focusing on launching formulated hyperphosphatemia drugs. Some of them include Sun Pharm Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fermenta Biotech Ltd, Bruno Pharmaceutical Spa, Pfizer Inc, DSM Biotech Pharmacal, Roche Diagnostics Corporation, Vifor Pharma, Fresenius Medical Care, Shire Amag Pharmaceuticals, Johnson and Johnson, Ultragenyx, Sanofi, Cipla, and R.H. Moore Drug Co.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
2.5. Estimation Methodology
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Iron-based Hyperphosphatemia Drugs Is A Game Changer
4. Market Determinants
4.1. Market Scope & Definition
4.2. Drivers
4.2.1. Growing Prevalence Of Chronic Diseases
4.2.2. Unmet Medical Needs
4.2.3. Skewed Population Mix Towards Elderly People
4.2.4. Rise In Public Awareness
4.3. Restraints
4.3.1. Limitations Levied By The Food And Drug Administration (Fda)
4.3.2. Growing Side Effects Of The Hyperphosphatemia Drugs
4.4. Challenges
4.4.1. Non-adherence To Treatment Regimens
4.4.2. Side Effects Of Drugs
4.4.3. Limited Availability Of Drugs
4.4.4. Use Of Advanced Dialysis Techniques
4.5. Market By Dosage
4.5.1. Solid
4.5.1.1. Tablet
4.5.1.2. Powder
4.5.2. Liquid
4.5.2.1. Solution
5. Market By Formulation
5.1.1. Calcium-based Phosphate Binders
5.1.2. Aluminum-based Phosphate Binders
5.1.3. Magnesium-based Phosphate Binders
5.1.4. Iron-based Phosphate Binders
5.1.5. Other Phosphate Binders
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Bargaining Power Of Buyers
6.1.3. Bargaining Power Of Suppliers
6.1.4. Threat Of Substitute Product
6.1.5. Intensity Of Competitive Rivalry
6.2. Opportunity Matrix
6.3. Key Buying Criteria
6.3.1. Application
6.3.2. Pricing
6.3.3. Effectiveness
6.3.4. Availability
6.4. Strategic Recommendation & Strategic Conclusions
6.5. Market Trends
6.5.1. Patient Assistance Programs
6.5.2. Strategic Alliances
6.5.3. Increase In R&D
6.6. Phosphate Binders Usages Guidelines
7. Geographic Analysis
7.1. Europe
7.1.1. The United Kingdom
7.1.2. France
7.1.3. Germany
7.1.4. Spain
7.1.5. Italy
7.1.6. Rest Of Europe (Roe)
8. Competitive Landscape
8.1. Market Share Analysis
8.2. Company Profiles
8.2.1. Amag Pharmaceuticals
8.2.1.1. Overview
8.2.1.2. Product Portfolio
8.2.1.3. Scot Analysis
8.2.1.4. Strategic Initiatives
8.2.2. Biotech Pharmacal
8.2.2.1. Overview
8.2.2.2. Products Portfolio
8.2.2.3. Scot Analysis
8.2.2.4. Strategic Initiatives
8.2.3. Bruno Farmaceutici Spa
8.2.3.1. Overview
8.2.3.2. Product Portfolio
8.2.3.3. Scot Analysis
8.2.3.4. Strategic Initiatives
8.2.4. Cipla
8.2.4.1. Overview
8.2.4.2. Product Portfolio
8.2.4.3. Scot Analysis
8.2.4.4. Strategic Initiatives
8.2.5. Fermenta Biotech Ltd
8.2.5.1. Overview
8.2.5.2. Product Portfolio
8.2.5.3. Scot Analysis
8.2.5.4. Strategic Initiatives
8.2.6. Fresenius Medical Care
8.2.6.1. Overview
8.2.6.2. Product Portfolio
8.2.6.3. Scot Analysis
8.2.6.4. Strategic Initiatives
8.2.7. Johnson And Johnson
8.2.7.1. Company Overview
8.2.7.2. Product Portfolio
8.2.7.3. Scot Analysis
8.2.7.4. Strategic Initiatives
8.2.8. Keryx Biopharmaceuticals Inc
8.2.8.1. Overview
8.2.8.2. Scot Analysis
8.2.8.3. Strategic Initiatives
8.2.9. Pfizer Inc.
8.2.9.1. Overview
8.2.9.2. Product Portfolio
8.2.9.3. Scot Analysis
8.2.9.4. Strategic Initiatives
8.2.10. Roche Diagnostics Corporation
8.2.10.1. Overview
8.2.10.2. Product Portfolio
8.2.10.3. Scot Analysis
8.2.10.4. Strategic Initiatives
8.2.11. Royal Dsm N.V.
8.2.11.1. Overview
8.2.11.2. Product Portfolio
8.2.11.3. Scot Analysis
8.2.11.4. Strategic Initiatives
8.2.12. Sanofi
8.2.12.1. Overview
8.2.12.2. Product Portfolio
8.2.12.3. Scot Analysis
8.2.12.4. Strategic Initiatives
8.2.13. Shire
8.2.13.1. Overview
8.2.13.2. Product Portfolio
8.2.13.3. Scot Analysis
8.2.13.4. Strategic Initiatives
8.2.14. Sun Pharmaceutical Industries Ltd
8.2.14.1. Overview
8.2.14.2. Products Portfolio
8.2.14.3. Scot Analysis
8.2.14.4. Strategic Initiatives
8.2.15. Ultragenyx Pharmaceutical Inc.
8.2.15.1. Overview
8.2.15.2. Product Portfolio
8.2.15.3. Scot Analysis
8.2.15.4. Strategic Initiatives
8.2.16. Zeria Pharmaceutical
8.2.16.1. Overview
8.2.16.2. Product Portfolio
8.2.16.3. Scot Analysis
8.2.16.4. Strategic Initiatives
List Of Tables
Table 1 Europe Hyperphosphatemia Drug Market 2019-2027($ Million)
Table 2 Iron-based Hyperphosphatemia Drug Approval Status 2014-2017
Table 3 Worldwide Population Aged 80 And Above 1950-2050 (Millions)
Table 4 Phosphorous Levels In Select Foods
Table 5 Europe Hyperphosphatemia Drugs Market By Formulation 2019-2027($ Million)
Table 6 Europe Calcium-based Phosphate Binders 2019-2027($ Million)
Table 7 Europe Aluminum-based Phosphate Binders 2019-2027($ Million)
Table 8 Europe Magnesium-based Phosphate Binders 2019-2027($ Million)
Table 9 Europe Iron-based Phosphate Binders 2019-2027($ Million)
Table 10 Europe Other Phosphate Binders 2019-2027($ Million)
Table 11 Pipeline Portfolio Of Hyperphosphatemia Drugs
Table 12 Europe Hyperphosphatemia Drugs Market 2019-2027 ($ Million)
Table 13 Europe Hyperphosphatemia Drugs Market By Country 2019-2027($ Million)
List Of Figures
Figure 1 Rate Of Adherence To Phosphate Binders
Figure 2 Diagnosis And Clinical Indicators Of Chronic Kidney Disease
Figure 3 Europe Hyperphosphatemia Drugs Market By Calcium-based Phosphate Binders 2019-2027($ Million)
Figure 4 Europe Hyperphosphatemia Drugs Market By Aluminum-based Phosphate Binders 2019-2027($ Million)
Figure 5 Europe Hyperphosphatemia Drugs Market By Magnesium-based Phosphate Binders 2019-2027($ Million)
Figure 6 Europe Hyperphosphatemia Drugs Market By Iron-based Phosphate Binders 2019-2027($ Million)
Figure 7 Europe Hyperphosphatemia Drugs Market By Other Phosphate Binders 2019-2027($ Million)
Figure 8 Porters 5 Force Model Of Hyperphosphatemia Market
Figure 9 Europe Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 10 The United Kingdom Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 11 France Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 12 Germany Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 13 Spain Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 14 Italy Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 15 Rest Of Europe Hyperphosphatemia Drugs Market 2019-2027($ Million)
Figure 16 Market Share Analysis Of Key Players 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report